ELIZABETH SHPALL to Drug Resistance, Neoplasm
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Drug Resistance, Neoplasm.
Connection Strength
0.237
-
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.
Score: 0.050
-
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-?B mediates chemoresistance. Blood. 2014 Apr 24; 123(17):2691-702.
Score: 0.043
-
Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70.
Score: 0.038
-
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 05 11; 6(1):509.
Score: 0.020
-
Chimeric Antigen Receptor T-Cell Therapy. J Natl Compr Canc Netw. 2018 09; 16(9):1092-1106.
Score: 0.015
-
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
Score: 0.014
-
A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017 02 09; 129(6):740-758.
Score: 0.013
-
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.
Score: 0.012
-
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct; 53(10):2024-32.
Score: 0.009
-
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108.
Score: 0.009
-
Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900.
Score: 0.008
-
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006 Jun 15; 106(12):2664-71.
Score: 0.006